Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru
Descripción del Articulo
Ivermectin has emerged as a therapeutic option for various parasitic diseases, including strongyloidiasis, scabies, lice infestations, gnathostomiasis, and myiasis. This study comprehensively reviews the evidence-based indications for ivermectin in treating parasitic diseases, considering the unique...
| Autores: | , , , , , , |
|---|---|
| Formato: | artículo |
| Fecha de Publicación: | 2023 |
| Institución: | Seguro Social de Salud |
| Repositorio: | ESSALUD-Institucional |
| Lenguaje: | inglés |
| OAI Identifier: | oai:repositorio.essalud.gob.pe:20.500.12959/5158 |
| Enlace del recurso: | https://hdl.handle.net/20.500.12959/5158 https://doi.org/10.1016/j.parepi.2023.e00320 |
| Nivel de acceso: | acceso abierto |
| Materia: | Ivermectin Antiparasitic agents Scientific evidence Helminthiasis Peru https://purl.org/pe-repo/ocde/ford#3.01.09 |
| id |
ESSA_59a9e7eac645545679d9cd614be5de41 |
|---|---|
| oai_identifier_str |
oai:repositorio.essalud.gob.pe:20.500.12959/5158 |
| network_acronym_str |
ESSA |
| network_name_str |
ESSALUD-Institucional |
| repository_id_str |
4277 |
| dc.title.es_PE.fl_str_mv |
Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru |
| title |
Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru |
| spellingShingle |
Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru Failoc-Rojas, Virgilio E. Ivermectin Antiparasitic agents Scientific evidence Helminthiasis Peru https://purl.org/pe-repo/ocde/ford#3.01.09 |
| title_short |
Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru |
| title_full |
Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru |
| title_fullStr |
Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru |
| title_full_unstemmed |
Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru |
| title_sort |
Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru |
| author |
Failoc-Rojas, Virgilio E. |
| author_facet |
Failoc-Rojas, Virgilio E. Silva-Díaz, Heber Maguiña, Jorge L. Rodriguez-Morales, Alfonso J. Díaz-Velez, Cristian Apolaya-Segura, Moises Valladares-Garrido, Mario J. |
| author_role |
author |
| author2 |
Silva-Díaz, Heber Maguiña, Jorge L. Rodriguez-Morales, Alfonso J. Díaz-Velez, Cristian Apolaya-Segura, Moises Valladares-Garrido, Mario J. |
| author2_role |
author author author author author author |
| dc.contributor.author.fl_str_mv |
Failoc-Rojas, Virgilio E. Silva-Díaz, Heber Maguiña, Jorge L. Rodriguez-Morales, Alfonso J. Díaz-Velez, Cristian Apolaya-Segura, Moises Valladares-Garrido, Mario J. |
| dc.subject.es_PE.fl_str_mv |
Ivermectin Antiparasitic agents Scientific evidence Helminthiasis Peru |
| topic |
Ivermectin Antiparasitic agents Scientific evidence Helminthiasis Peru https://purl.org/pe-repo/ocde/ford#3.01.09 |
| dc.subject.ocde.es_PE.fl_str_mv |
https://purl.org/pe-repo/ocde/ford#3.01.09 |
| description |
Ivermectin has emerged as a therapeutic option for various parasitic diseases, including strongyloidiasis, scabies, lice infestations, gnathostomiasis, and myiasis. This study comprehensively reviews the evidence-based indications for ivermectin in treating parasitic diseases, considering the unique context and challenges in Peru. Fourteen studies were selected from a systematic search of scientific evidence on ivermectin in PubMed, from 2010 to July 2022. The optimal dosage of ivermectin for treating onchocerciasis, strongyloidiasis, and enterobiasis ranges from 150 to 200 μg/kg, while lymphatic filariasis requires a higher dose of 400 μg/kg (Brown et al., 2000). However, increased dosages have been associated with a higher incidence of ocular adverse events. Scientific evidence shows that ivermectin can be safely and effectively administered to children weighing less than 15 kg. Systematic reviews and meta-analyses provide strong support for the efficacy and safety of ivermectin in combating parasitic infections. Ivermectin has proven to be an effective treatment for various parasitic diseases, including intestinal parasites, ectoparasites, filariasis, and onchocerciasis. Dosages ranging from 200 μg/kg to 400 μg/kg are generally safe, with adjustments made according to the specific pathology, patient age, and weight/height. Given Peru's prevailing social and environmental conditions, the high burden of intestinal parasites and ectoparasites in the country underscores the importance of ivermectin in addressing these health challenges. |
| publishDate |
2023 |
| dc.date.accessioned.none.fl_str_mv |
2024-10-01T14:55:20Z |
| dc.date.available.none.fl_str_mv |
2024-10-01T14:55:20Z |
| dc.date.issued.fl_str_mv |
2023-11-01 |
| dc.type.es_PE.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.citation.es_PE.fl_str_mv |
Parasite Epidemiology and Control. 2023; 23. |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.12959/5158 |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1016/j.parepi.2023.e00320 |
| identifier_str_mv |
Parasite Epidemiology and Control. 2023; 23. |
| url |
https://hdl.handle.net/20.500.12959/5158 https://doi.org/10.1016/j.parepi.2023.e00320 |
| dc.language.iso.es_PE.fl_str_mv |
eng |
| language |
eng |
| dc.relation.uri.es_PE.fl_str_mv |
https://www.sciencedirect.com/science/article/pii/S2405673123000375 |
| dc.rights.es_PE.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.uri.es_PE.fl_str_mv |
https://creativecommons.org/licenses/by-nc-sa/4.0/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/4.0/ |
| dc.format.es_PE.fl_str_mv |
application/pdf |
| dc.publisher.es_PE.fl_str_mv |
World Federation of Parasitologists |
| dc.source.none.fl_str_mv |
reponame:ESSALUD-Institucional instname:Seguro Social de Salud instacron:ESSALUD |
| instname_str |
Seguro Social de Salud |
| instacron_str |
ESSALUD |
| institution |
ESSALUD |
| reponame_str |
ESSALUD-Institucional |
| collection |
ESSALUD-Institucional |
| bitstream.url.fl_str_mv |
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/5158/1/Evidence-based%20indications%20for%20ivermectin%20in%20parasitic%20diseases.%20An%20integrated%20approach%20to%20context%20and%20challenges%20in%20Peru.pdf https://repositorio.essalud.gob.pe/bitstream/20.500.12959/5158/2/license.txt https://repositorio.essalud.gob.pe/bitstream/20.500.12959/5158/3/Evidence-based%20indications%20for%20ivermectin%20in%20parasitic%20diseases.%20An%20integrated%20approach%20to%20context%20and%20challenges%20in%20Peru.pdf.txt https://repositorio.essalud.gob.pe/bitstream/20.500.12959/5158/4/Evidence-based%20indications%20for%20ivermectin%20in%20parasitic%20diseases.%20An%20integrated%20approach%20to%20context%20and%20challenges%20in%20Peru.pdf.jpg |
| bitstream.checksum.fl_str_mv |
ae2d4d40e5ef47d0b3820e482c4da980 8a4605be74aa9ea9d79846c1fba20a33 82f09acd329ee70a34687677cfa5a752 a03d86157b7a33d77ef0333a2f1e9c09 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Seguro Social de Salud – ESSALUD |
| repository.mail.fl_str_mv |
bibliotecacentral@essalud.gob.pe |
| _version_ |
1813537115330314240 |
| spelling |
Failoc-Rojas, Virgilio E.Silva-Díaz, HeberMaguiña, Jorge L.Rodriguez-Morales, Alfonso J.Díaz-Velez, CristianApolaya-Segura, MoisesValladares-Garrido, Mario J.2024-10-01T14:55:20Z2024-10-01T14:55:20Z2023-11-01Parasite Epidemiology and Control. 2023; 23.https://hdl.handle.net/20.500.12959/5158https://doi.org/10.1016/j.parepi.2023.e00320Ivermectin has emerged as a therapeutic option for various parasitic diseases, including strongyloidiasis, scabies, lice infestations, gnathostomiasis, and myiasis. This study comprehensively reviews the evidence-based indications for ivermectin in treating parasitic diseases, considering the unique context and challenges in Peru. Fourteen studies were selected from a systematic search of scientific evidence on ivermectin in PubMed, from 2010 to July 2022. The optimal dosage of ivermectin for treating onchocerciasis, strongyloidiasis, and enterobiasis ranges from 150 to 200 μg/kg, while lymphatic filariasis requires a higher dose of 400 μg/kg (Brown et al., 2000). However, increased dosages have been associated with a higher incidence of ocular adverse events. Scientific evidence shows that ivermectin can be safely and effectively administered to children weighing less than 15 kg. Systematic reviews and meta-analyses provide strong support for the efficacy and safety of ivermectin in combating parasitic infections. Ivermectin has proven to be an effective treatment for various parasitic diseases, including intestinal parasites, ectoparasites, filariasis, and onchocerciasis. Dosages ranging from 200 μg/kg to 400 μg/kg are generally safe, with adjustments made according to the specific pathology, patient age, and weight/height. Given Peru's prevailing social and environmental conditions, the high burden of intestinal parasites and ectoparasites in the country underscores the importance of ivermectin in addressing these health challenges.application/pdfengWorld Federation of Parasitologistshttps://www.sciencedirect.com/science/article/pii/S2405673123000375info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/IvermectinAntiparasitic agentsScientific evidenceHelminthiasisPeruhttps://purl.org/pe-repo/ocde/ford#3.01.09Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peruinfo:eu-repo/semantics/articlereponame:ESSALUD-Institucionalinstname:Seguro Social de Saludinstacron:ESSALUDORIGINALEvidence-based indications for ivermectin in parasitic diseases. An integrated approach to context and challenges in Peru.pdfEvidence-based indications for ivermectin in parasitic diseases. An integrated approach to context and challenges in Peru.pdfapplication/pdf946264https://repositorio.essalud.gob.pe/bitstream/20.500.12959/5158/1/Evidence-based%20indications%20for%20ivermectin%20in%20parasitic%20diseases.%20An%20integrated%20approach%20to%20context%20and%20challenges%20in%20Peru.pdfae2d4d40e5ef47d0b3820e482c4da980MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.essalud.gob.pe/bitstream/20.500.12959/5158/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52TEXTEvidence-based indications for ivermectin in parasitic diseases. An integrated approach to context and challenges in Peru.pdf.txtEvidence-based indications for ivermectin in parasitic diseases. An integrated approach to context and challenges in Peru.pdf.txtExtracted texttext/plain36238https://repositorio.essalud.gob.pe/bitstream/20.500.12959/5158/3/Evidence-based%20indications%20for%20ivermectin%20in%20parasitic%20diseases.%20An%20integrated%20approach%20to%20context%20and%20challenges%20in%20Peru.pdf.txt82f09acd329ee70a34687677cfa5a752MD53THUMBNAILEvidence-based indications for ivermectin in parasitic diseases. An integrated approach to context and challenges in Peru.pdf.jpgEvidence-based indications for ivermectin in parasitic diseases. An integrated approach to context and challenges in Peru.pdf.jpgGenerated Thumbnailimage/jpeg6750https://repositorio.essalud.gob.pe/bitstream/20.500.12959/5158/4/Evidence-based%20indications%20for%20ivermectin%20in%20parasitic%20diseases.%20An%20integrated%20approach%20to%20context%20and%20challenges%20in%20Peru.pdf.jpga03d86157b7a33d77ef0333a2f1e9c09MD5420.500.12959/5158oai:repositorio.essalud.gob.pe:20.500.12959/51582024-10-02 03:00:51.153Repositorio Seguro Social de Salud – ESSALUDbibliotecacentral@essalud.gob.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 |
| score |
13.888049 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).